Tarsus Pharmaceuticals, Inc. TARS Deferred Tax Assets, Goodwill and Intangible Assets
Deferred Tax Assets, Goodwill and Intangible Assets at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets.
The official record: Tarsus Pharmaceuticals, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Tarsus Pharmaceuticals, Inc.'s deferred tax assets, goodwill and intangible assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Tarsus Pharmaceuticals, Inc.'s deferred tax assets, goodwill and intangible assets?
- Tarsus Pharmaceuticals, Inc. (TARS) reported deferred tax assets, goodwill and intangible assets of $3.58M in Q4 2025.
- How has Tarsus Pharmaceuticals, Inc.'s deferred tax assets, goodwill and intangible assets changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s deferred tax assets, goodwill and intangible assets decreased by 2.3% year-over-year, from $3.66M to $3.58M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s deferred tax assets, goodwill and intangible assets?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s deferred tax assets, goodwill and intangible assets has grown at a 27.9% compound annual growth rate (CAGR), from $1.05M to $3.58M.